Impact of SARS-CoV-2 Omicron on Rapid Antigen Testing Developed for Early-Pandemic SARS-CoV-2 Variants

Karoline Leuzinger,a,b Tim Roloff,c,d Adrian Egli,c,d Hans H. Hirsch,a,b,e

aClinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland
bTransplantation & Clinical Virology, Department Biomedicine, University of Basel, Basel, Switzerland
cApplied Microbiology Research, Laboratory Medicine, Department Biomedicine, University of Basel, Basel, Switzerland
dClinical Bacteriology and Mycology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland
eInfectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland

ABSTRACT
Rapid antigen tests (RATs) are widely used for point-of-care or self-testing to identify SARS-CoV-2 (SCoV2), but currently circulating Omicron variants may impair detection. In this study, we prospectively evaluated the Roche-SARS-CoV-2-Antigen and Acon-FlowFlex-SARS-CoV-2-Antigen in 150 consecutively collected nasopharyngeal patient swabs (50 SCoV2 RNA undetectable; 100 SCoV2 Omicron BA.1). Omicron BA.1 results were compared to 92 Ct-matched early-pandemic SCoV2 variants (B.1.160 and B.1.177), to 100 Omicron BA.2 positive and to 100 Omicron BA.5 positive samples. For Omicron BA.1, Roche-SARS-CoV-2-Antigen detected 87% of samples having Ct-values <29 reflecting 3.6% lower rates compared to B.1.160 and B.1.177. Acon-FlowFlex-SARS-CoV-2-Antigen was less affected and detected 90% of Omicron BA.1 with Ct-values <29. Omicron BA.2 and BA.5 detection rates were significantly reduced by 20% and 10%, respectively, for the Roche-SARS-CoV-2-Antigen in samples with Ct-values <29 but remained similar for Acon-FlowFlex-SARS-CoV-2-Antigen. RATs need to be continuously evaluated as new SCoV2-variants emerge. Spreading of Omicron-BA.2, and the recently emerged Omicron BA.5 variant, may not only result from escape from postvaccine or postinfection immunity, but also from false-negative RATs misguiding point-of-care and self-testing decisions at times of restricted molecular testing.

IMPORTANCE
Antigen tests are widely used for rapid identification of SCoV2-positive cases and their increased risk of transmission. At present, there are several FDA- and CE-cleared tests available in North America and Europe. However, their diagnostic performance has been evaluated with early-pandemic variants. This study provides evidence that variation within the nucleocapsid protein as seen in recently emerged and now globally spreading Omicron BA.2 and BA.5 variants significantly impairs detection rates of widely used antigen tests. Consequently, antigen tests need to be reevaluated when new pandemic SCoV2 variants emerge and start to predomin ate globally.

KEYWORDS severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, Omicron, variant, COVID-19, BA.2, BA.5, rapid antigen tests, RAT
globally dominating Omicron variants ([https://nextstrain.org/ncov/gisaid/global](https://nextstrain.org/ncov/gisaid/global)). Importantly, Omicron strains harbor a number of mutations in the otherwise rather conserved nucleocapsid protein (BA.1, BA.2 and BA.5: P13L, Δ31-33, R203K, G204R; and for BA.2 and BA.5 additionally S413R; [https://covariants.org/variants/21K.Omicron](https://covariants.org/variants/21K.Omicron)) that may potentially impair antigen detection rates. In this prospective clinical validation study, we analyzed nasopharyngeal swabs from patients with and without NAT confirmed SCoV2 infection and prospectively assessed the diagnostic performance of the Roche-SARS-CoV-2-Antigen that has received emergency use authorization (EUA) by the food and drug administration (FDA) and is widely employed in Northern American and European health care. Results were compared to Ct-matched early-pandemic SCoV2 variants (B.1.160 and B.1.177) and the Acon-FlowFlex-SARS-CoV-2-Antigen that is widely available in retail and pharmacy stores.

**RESULTS**

**Prospective evaluation of the Roche-SARS-CoV-2-Antigen.** From January 25 to February 28, 2022, SCoV2 specific NAT testing was done using the cobas SARS-CoV-2 test on the cobas6800 platform from 150 nasopharyngeal patient swabs and analyzed in parallel with the Roche-SARS-CoV-2-Antigen. All 50 SCoV2 RNA negative samples were also non-reactive in the Roche-SARS-CoV-2-Antigen (specificity of 100%; 95%CI: 92.9% to 100%). Of 100 Omicron BA.1 positive samples, 80 (80%) were detected by the Roche-SARS-CoV-2-Antigen. Omicron BA.1 positive samples with low SCoV2 RNA loads requiring Ct-values of >30 (n = 8) were non-reactive in the Roche-SARS-CoV-2-Antigen. For samples with Ct-values <29 (approximately 10,000 copies/mL or 4 log₁₀ c/mL), sensitivity was 87% (95%CI: 78.3% to 93.1%) with a negative predictive value (NPV) of 98.6% at current local SCoV2 prevalence of <10% ([https://www.covid19.admin.ch/de/overview](https://www.covid19.admin.ch/de/overview)). The Roche-SARS-CoV-2-Antigen sensitivity significantly increased with SCoV2 loads, having a sensitivity of 94% (95%CI: 86.2% to 98.0%) in samples with Ct-values <26 (approximately 100'000 c/mL or 5 log₁₀ c/mL), and 100% (95%CI: 93.4% to 100%) in samples with Ct-values <23 (approximately 1 million c/mL or 6 log₁₀ c/mL).

**SCoV2 early-pandemic and Omicron variant detection by the Roche-SARS-CoV-2-Antigen.** To evaluate the diagnostic performance of the Roche-SARS-CoV-2 RAT for Omicron BA.1 and earlier SCoV2 variants (B.1.160 and B.1.177), 92 Ct-matched nasopharyngeal patient swabs from a previous study (1) were identified and compared to the current data set. By comparison, the Roche-SARS-CoV-2-Antigen rates for B.1.160 and B.1.177 were higher by 3.5%, 2.5% and 0.0% in samples with Ct-values of 29, 26 and 23. Thus, 90% detection rates in patient swabs required Ct-values <26 for Omicron BA.1, compared to Ct-values <29 for early-pandemic variants (Fig. 1A and D), corresponding to a 10-fold higher SCoV2 RNA load.

**Comparison of the Roche-SARS-CoV-2-Antigen and Acon-FlowFlex-SARS-CoV-2.** To examine the performance of another independent RAT, the 150 nasopharyngeal patient swabs were additionally analyzed by the Acon-FlowFlex-SARS-CoV-2. Of 100 Omicron BA.1 positive samples, 79 (79%) were concordant-positive, 17 (17%) concordant-negative, and 4 (4%) discordant results. The four discordant samples were Acon-FlowFlex-SARS-CoV-2-positive/Roche-SARS-CoV-2-negative and showed Ct-values >25. Overall, Acon-FlowFlex-SARS-CoV-2 antigen positivity rates were significantly increased compared to Roche-SARS-CoV-2 (P < 0.001; Fig. 1B), with >90% Omicron BA.1 detection in clinical patient swabs with Ct-values <29, compared to 87% for Roche-SARS-CoV-2-Antigen (Fig. 1D).

**Comparison of Omicron BA.1, BA.2, and BA.5 detection.** Lastly, we compared Omicron BA.1, Omicron BA.2 and Omicron BA.5 variant detection with the Roche-SARS-CoV-2 and Acon-FlowFlex-SARS-CoV-2 RATs. Omicron BA.2 and Omicron BA.5 positive nasopharyngeal patient swabs were analyzed in parallel by the Roche-SARS-CoV-2 and Acon-FlowFlex-SARS-CoV-2 RATs, and results were compared to 100 Ct-value matched BA.1 positive patient swabs (Fig. 1C). Compared to Omicron BA.1, Omicron BA.2 significantly reduced (P < 0.01) detection rates by 20% for the Roche-SARS-CoV-2 in samples with Ct-values <29, while it did not affect Acon-FlowFlex-SARS-CoV-2 sensitivity. Similarly, Omicron BA.5 detection rates were significantly reduced by 10% for the Roche-SARS-CoV-2 RAT in samples with Ct-values <29 (P = 0.014), but remained similar for Acon-FlowFlex-SARS-CoV-2 (Fig. 1C and D).
**DISCUSSION**

Rapid antigen tests are widely used for point-of-care or for self-testing to readily identify SCoV2 infection for epidemiologic and therapeutic purposes. In this study, we prospectively assessed the diagnostic performance of the Roche-SARS-CoV-2 Antigen that is widely employed in Northern American and European health care, and the Acon-FlowFlex-SARS-CoV-2 Antigen that is widely available in retail and pharmacy stores. Our study has three major findings:

First, Roche-SARS-CoV-2-Antigen and Acon-FlowFlex-SARS-CoV-2-Antigen RATs remain effective in detecting the SCoV2 Omicron BA.1 variant in clinical nasopharyngeal swab samples with high viral loads despite extensive mutations in the nucleocapsid protein. Thus, timely decision-making remains reliable for persons with highly infectious Omicron BA.1
titers as seen in persons with little or no SCoV2-specific immunity and persons presenting early in the natural course of infection (2).

Second, the sensitivity of the Roche-SARS-CoV-2-Antigen is reduced for Omicron BA.1 compared to the early-pandemic SCoV2 variants B.1.160 and B.1.177 at lower SCoV2 loads (Ct-values >26), corresponding to SCoV2 loads of approximately 100,000 copies/mL. Thus, in vaccinated persons and those presenting late in the natural course of infection, RATs like the Roche-SARS-CoV-2-Antigen may not deliver reliable diagnostics of SCoV2/CoVID19 and a molecular test is preferred. Indeed, SCoV2 loads typically decrease by 3 log_{10} c/mL over a period of 10 days in unvaccinated patients even in the absence of effective antivirals or monoclonal antibodies (3). Conversely, vaccinated individuals have been reported to clear SCoV2 faster than unvaccinated patients (4), thereby reducing the SCoV2 transmission risk as Ct-values increase from 26 to 29 (5).

Third, not all RATs behaved similarly as the Acon-FlowFlex-SARS-CoV-2-Antigen showed a slightly better detection rate in Omicron positive samples with lower SCoV2 loads (Ct-values of 26 to 29). This trend to better detection became highly significant for the emerging Omicron BA.2 and BA.5 variants.

Finally, unlike the Acon-FlowFlex-SARS-CoV-2-Antigen, the Roche-SARS-CoV-2-Antigen was dramatically impaired in detecting the Omicron BA.2 and to a lesser degree the Omicron BA.5 variant. As the diagnostic performance of the majority of commercially available RATs is based on the use of monoclonal antibodies against specific domains of the viral nucleocapsid protein, already single amino acid exchanges, such as S413R, may significantly decrease target binding and subsequent detection rates. This poses an important diagnostic issue as Omicron BA.5 is more transmissible than BA.1, and thus have become more prevalent worldwide.

In conclusion, Roche-SARS-CoV-2-Antigen remains effective to detect Omicron BA.1 in patient samples with high SCoV2 loads, but detection of Omicron BA.2 and Omicron BA.5 is impaired. The Acon-FlowFlex-SARS-CoV-2-Antigen showed a better detection rate underlining the fact that there are substantial differences between commercially available RATs. We conclude that RATs need to be continuously evaluated as new pandemic SCoV2 variants emerge. We suggest that public health authorities should provide guidance how to appropriately define relicensing requirements. Importantly, spreading of the new Omicron BA.5 variant may not only result from postvaccine or postinfection immune escape, but also from false-negative rapid antigen testing misguiding point-of-care and self-testing decisions.

**MATERIALS AND METHODS**

**Clinical specimens and SCoV2 NAT testing.** Nasopharyngeal sites were swabbed from 150 consecutive outpatients presenting to the CoVID-19 Triage and Test Center at UHB for SCoV2 specific NAT testing from January 25th to February 28th, 2022 (6). Swabs were collected in universal transport medium (UTM; Copan; Brescia, Italy), and analyzed using the cobas SARS-CoV-2 test on the cobas6800 platform (Roche) as described (3). Cobas SARS-CoV-2 Target 1 (ORF1a/b) Ct-values were used to assess RAT performance. Omicron BA.1 was confirmed in the 100 SCoV2-positive nasopharyngeal swabs. As Omicron BA.2 and BA.5 harbor the additional nucleocapsid mutation S413R, we obtained 100 Omicron BA.2 and 100 Omicron BA.5 positive nasopharyngeal swabs from consecutive outpatients at UHB from March 8 to July 15, 2022.

**SCoV2 Omicron identification.** From all SCoV2 RNA positive samples, identification, and differentiation of Omicron BA.1, BA.2 and BA.5 was performed using three SCoV2 variant specific NATs, following the NAT cycling protocol described in (7) (for primers and probes see Table 1). The only adaptation in NAT cycling conditions was annealing and extension for 60 s at 50°C (E484A and Del96/70-NATs) and 56°C (N50Y-NAT), respectively.

**SCoV2 antigen testing.** For the prospective evaluation of the Roche-SARS-CoV-2-Antigen and Acon-FlowFlex-SARS-CoV-2-Antigen RATs, we assessed 100 consecutive SCoV2 Omicron BA.1 positive and 50 consecutive SCoV2 RNA negative, as well as 100 Omicron BA.2 and 100 Omicron BA.5 positive UTM samples. All samples were stored at 4°C and used within 24 h from collection. RATs were performed according to the manufacturers’ instructions. Briefly, UTM samples were brought to room-temperature and 300 µL UTM was added to the extraction buffer (1:1 ratio). Three drops were added to the device and read-out was performed after 20 Min as described (1).

**Statistical methods.** Sensitivity and specificity of each RAT was calculated according to results from SCoV2-specific NAT testing. Receiver operating characteristic analysis (ROC) was done using the sensitivities of each RAT stratified by SCoV2-RNA-loads. All statistical data analysis was done in R (version3.6.1; https://cran.r-project.org), using Prism (version8; GraphPad Software, CA, USA) for data visualization. Mann–Whitney-U test was used as indicated. To evaluate the diagnostic performance of the Roche-SARS-CoV-2-Antigen RAT for
Rapid Antigen Testing for Omicron Variants

Microbiology Spectrum

July/August 2022 Volume 10 Issue 4 10.1128/spectrum.02006-22 5

**TABLE 1** Forward primer, reverse primer, and probes of the Del96/70, E484A and N501Y NATs

| Mutation | Primer/probe          | Sequence (5′→3′)                  | Positiona |
|----------|-----------------------|-----------------------------------|-----------|
| Del96/70 | Forward primer        | CTTACCTTTTCTTTTCC                  | 23017–23142 |
|          | Reverse primer        | GTGTTACAAACCTCTTAG                 | 21800–21870 |
|          | Probe wild type       | GTTCCATGCTATAACA                   | 21753–21768 |
|          | Probe mutant-version1 | GTCCATGCTATCCTCT                  | 21754–21768 |
|          | Probe mutant-version2 | GTTCCATGCTATCCTCT                  | 21753–21768 |
| E484A    | Forward primer        | ACTGAAATCTATCAGG                   | 22970–23060 |
|          | Reverse primer- version1 | TGTAAGGAGGAGTAAC                 | 23040–23070 |
|          | Reverse primer- version2 | CGTAAAGGAAAGTAAC                   | 23040–23070 |
|          | Probe wild type       | TGTAATGTTGTGAA                     | 23000–23014 |
|          | Probe mutant          | TTGTAATGTTGTGCA                    | 23001–23014 |
| N501Y    | Forward primer- version1 | AAGGTTTTAATTGGTTACTTCC         | 23013–23034 |
|          | Forward primer- version2 | CAGGTGTTTTAATTGGTTACTTCC       | 23013–23034 |
|          | Reverse primer        | GAAATCAGAAGAAGACTACT              | 23114–23093 |
|          | Probe wild type       | TTTCAACCCACTTTAGG                 | 23051–23067 |
|          | Probe mutant-version1 | TTTCAACCCACTTTAGG                 | 23051–23067 |
|          | Probe mutant-version2 | TTTCAACCCACTTTAGG                 | 23051–23067 |

aPositions according to SARS-CoV-2 isolate Wuhan-Hu-1 (acc. no. NC_045512.2).

Omicron BA.1 and earlier SCoV2 variants (B.1.160 and B.1.177) (1), Ct-matched UTM-samples were identified and compared to the current data set.

**ACKNOWLEDGMENTS**

We thank the biomedical analysts, especially Barbara Hochuli and Veronika del Zenero, of the Clinical Virology, University Hospital Basel, Basel, Switzerland and Transplantation & Clinical Virology, Department Biomedicine, Basel, Switzerland, for expert help and assistance.

The study was conducted according to good laboratory practice and in accordance with the Declaration of Helsinki and national and institutional standards for laboratory quality control and was approved by the Ethical Committee of North-Western and Central Switzerland (EKNZ 2020).

K.L. and H.H.H. designed the study, validated results, extracted data, performed analyses, reviewed data, and wrote the manuscript; T.R., and A.E. reviewed data and contributed to writing the manuscript.

We have no conflicts of interest to declare.

This study was supported by the Clinical Virology Division, Laboratory Medicine, University Hospital Basel, Basel, Switzerland, and appointment grant to H.H.H., Department Biomedicine, University of Basel, Basel, Switzerland.

**REFERENCES**

1. Greub G, Caruana G, Schweitzer M, Imperiali M, Muigg V, Risch M, Croxatto A, Opota O, Heller S, Albertos Torres D, Tritten ML, Leuzzi K, Hirsch HH, Lienhard R, Egli A. 2021. Multicenter technical validation of 30 rapid antigen tests for the detection of SARS-CoV-2 (VALIDATE). Microorganisms 9:2589. https://doi.org/10.3390/microorganisms9122589.
2. Leuzzi K, Osthoff M, Dräger S, Pargger H, Siegemund M, Bassetti S, Bingisser R, Nickel CH, Tschudin-Sutter S, Khanna N, Rentsch K, Battegay M, Egli A, Hirsch HH. 2021. Comparing immunoassays for SARS-CoV-2 antibody detection in patients with and without laboratory-confirmed SARS-CoV-2 infection. J Clin Microbiol 59:10138121. https://doi.org/10.1128/JCM.01381-21.
3. Leuzzi K, Gosert R, Sogaard KK, Naegele K, Bielicki J, Roloff T, Bingisser R, Nickel CH, Khanna N, Sutter ST, Widmer AF, Rentsch K, Pargger H, Siegemund M, Stolz D, Tammi M, Bassetti S, Osthoff M, Battegay M, Egli A, Hirsch HH. 2021. Epidemiology and precision of SARS-CoV-2 detection following lockdown and relaxation measures. J Med Virol 93:2374–2384. https://doi.org/10.1002/jmv.26731.
4. Puhach O, Adeka K, Hulo N, Sattanont-Rocher P, Genecand C, Iten A, Bausch FJ, Kaiser L, Vetter P, Eckerle I. 2022. Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron. MedRxiv. https://www.medrxiv.org/content/10.1101/2022.01.10.22269010v2.
5. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, Walker AS, Peto TE. 2022. Effect of Covid-19 vaccination on transmission of Alpha and Delta variants. N Engl J Med 386:744–756. https://doi.org/10.1056/NEJMoa2116597.
6. Mansella G, Rueegg M, Widmer AF, Tschudin-Sutter S, Battegay M, Hoff J, Sogaard KK, Egli A, Stellets J, Leuzzi K, Hirsch HH, Meienberg A, Burkard T, Mayr M, Bingisser R, Nickel CH. 2020. COVID-19 triage and test center: safety, feasibility, and outcomes of low-threshold testing. JCM 9:3217. https://doi.org/10.3390/jcm9103217.
7. Leuzzi K, Roloff T, Gosert R, Sogaard K, Naegele K, Rentsch K, Bingisser R, Nickel CH, Pargger H, Bassetti S, Bielicki J, Khanna N, Tschudin Sutter S, Widmer A, Hinic V, Battegay M, Egli A, Hirsch HH. 2020. Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 emergence amidst community-acquired respiratory viruses. J Infect Dis 222:1270–1279. https://doi.org/10.1093/infdis/jiaa464.